Rheumatology

Corrective Exercise Book "Built from Broken" Promises to Help Rebuild Joints and Relieve Pain Naturally

Retrieved on: 
Friday, June 18, 2021
Joint, Skeletal system, Orthopedic surgery, Arthritis, Health, Rheumatology, Connective tissue diseases, Branches of biology

PALM CITY, Fla., June 18, 2021 /PRNewswire/ --A book published by therapeutic sports nutrition company, SaltWrap, promises to help relieve joint pain and rebuild connective tissuesnaturally.

Key Points: 
  • PALM CITY, Fla., June 18, 2021 /PRNewswire/ --A book published by therapeutic sports nutrition company, SaltWrap, promises to help relieve joint pain and rebuild connective tissuesnaturally.
  • "We have much more control over how our joints adapt to physical stimuli than most people realize," said Scott Hogan, author of "Built from Broken" and Certified Orthopedic Exercise Specialist.
  • "Just like muscles, our joints are constantly going through a process of breakdown and repair.
  • Part 2 provides a complete overarching exercise plan to heal painful joints and build a strong, functional body that stands the test of time.

$4.7 Billion Autoimmune Diseases Diagnostics Global Market to 2026 - Technological Innovation in the Form of Lab Automation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Science, Health, Other Science, Other Health, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Rheumatology, Immunology, Connective tissue diseases, Autoimmunity, Arthritis, Autoimmune disease, Type 1 diabetes, Anti-SSA/Ro autoantibodies

The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • An autoimmune disease is a disorder wherein one's immune system attacks the body and destroys its body tissue.
  • There have been around 80 different types of autoimmune disorders being identified, of which, multiple sclerosis, type 1 diabetes, rheumatoid arthritis are fairly common.
  • Factors such as a rise in the incidence of autoimmune diseases have been a major driver for the growth of the market of autoimmune drugs.

Dr. Jarrad Martin, D.C. Publishes Book Offering Breakthroughs for Joint Pain

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Skeletal disorders, Pain management, Arthritis, Chronic pain, Arthralgia, Osteoarthritis, Back pain, Undertreatment of pain

After over 7 years of successfully treating patients with chronic pain from degenerative arthritis, Dr. Martin founded Ridgeview Medical.

Key Points: 
  • After over 7 years of successfully treating patients with chronic pain from degenerative arthritis, Dr. Martin founded Ridgeview Medical.
  • This way Ridgeview Medical can offer an array of diagnostic and treatment options, from multiple healthcare practitioners, all under one roof.
  • "Joint pain can be so debilitating, I wanted to share my knowledge about treating it with as wide an audience as possible," explained Dr. Martin.
  • That way, they can be confident that they are getting the best available treatment for their joint pain."

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Medicine, Clinical medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Arthritis, Rheumatoid arthritis, Precision medicine, Sjögren syndrome

The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.

Key Points: 
  • The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.
  • The study found a EULAR-based inadequate response in 37 out of the 68 patients, or 54.4%.
  • The successful validation of the novel test for EULAR inadequate response in this treat-to-target setting is promising, said Johanna Withers , Ph.D., study co-author, and Principal Scientist at Scipher Medicine.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

Retrieved on: 
Tuesday, June 15, 2021
Health sciences, Medicine, Clinical medicine, Norepinephrine reuptake inhibitors, Fibromyalgia, Rheumatology, Esreboxetine, Reuptake inhibitor

The NDA submission is currently anticipated in the fourth quarter of 2022 pending successful completion of manufacturing and other activities related to the product candidate.

Key Points: 
  • The NDA submission is currently anticipated in the fourth quarter of 2022 pending successful completion of manufacturing and other activities related to the product candidate.
  • Acceptance of the NDA will be subject to the FDAs review of the complete filing.
  • AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options.

2021 Runners' Guide to Healthy Knees Now Available From CopperJoint

Retrieved on: 
Monday, June 14, 2021
Clinical medicine, Knee pain, Rheumatology, Health, Knee, Medicine

Today's release of the 2021 Runners' Guide to Healthy Knees continues this journey and evolution in knee health, common ailments and recovery option guides.

Key Points: 
  • Today's release of the 2021 Runners' Guide to Healthy Knees continues this journey and evolution in knee health, common ailments and recovery option guides.
  • In April2021, CopperJoint first published a 2021 Knee Health Guide .This was followed by the 2021 Knee Health FAQs Guide , which provided answers to commonly asked knee-heath questions.
  • Today, CopperJoint.com continues their commitment to education, health, and wellness by publishing the 2021 Runners' Guide to Healthy Knees .
  • The new 2021 Runners' Guide to Healthy Knees also explores ways to recover from knee pain to get people whosuffer back on their feet and pain-free.

Sunny Bay Launches Unscented Neck and Shoulder Wrap to Rave Reviews

Retrieved on: 
Monday, June 14, 2021
Clinical medicine, Arthritis, Rheumatology, Health

FEDERAL WAY, Wash., June 14, 2021 /PRNewswire/ --Washington-based Sunny-Bay, a manufacturer and retailer of high-quality pain relief products, announced its recent launch of a microwavable moist neck and shoulder wrap to concurrently combat both neck and shoulder discomfort.

Key Points: 
  • FEDERAL WAY, Wash., June 14, 2021 /PRNewswire/ --Washington-based Sunny-Bay, a manufacturer and retailer of high-quality pain relief products, announced its recent launch of a microwavable moist neck and shoulder wrap to concurrently combat both neck and shoulder discomfort.
  • Unique in stress and pain relief, this heat wrap is a must-have gift at the end of the pandemic to rewind.
  • Used as a heat wrap by warming in a microwave, its unscented hydra-beads balance temperature across chambers and won't shift or burn.
  • The wrap is both weighted and contoured to stay put and ease radiating headaches, arthritis, and muscle stiffness simultaneously in both the neck and shoulder region.

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Arthritis, Autoimmune diseases, Rheumatology, Ankylosing spondylitis, Axial spondyloarthritis, G protein-coupled receptors, Spondyloarthropathy, Interleukin-1 family, Prostaglandin E

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT.
  • The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Philip J. Clements, MD, MPH, MACR, is recognized by Continental Who's Who

Retrieved on: 
Friday, June 11, 2021
Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Rheumatology, Mucinoses, Syndromes, Rare diseases, Raynaud syndrome, Scleroderma, David Geffen School of Medicine at UCLA

For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.

Key Points: 
  • For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.
  • He is devoted to educating future medical professionals as an Emeritus Professor of Medicine for the David Geffen School of Medicine at UCLA.
  • As a Rheumatologist, he has been a key opinion leader in Scleroderma and Raynaud's disease and has conducted many clinical trials.
  • He would also like to recognize his beautiful family his wife of 35 years, Ellie, and his children, Philip Jr, Annette, and David.

CreakyJoints Reports that Women Endure Symptoms of Inflammatory Arthritis Despite Availability of Medications Proven Safe for Pregnant and Lactating Mothers

Retrieved on: 
Friday, June 11, 2021
General Health, Women, Consumer, Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Arthritis, Hepatotoxins, Biotechnology, Rheumatoid arthritis, Nonsteroidal anti-inflammatory drug, Biopharmaceutical, TNF inhibitor

Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.

Key Points: 
  • Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.
  • Among those who were prescribed TNFis, 18 percent of women continued these medications through pregnancy post-2012 versus only 5 percent of women who continued these medications pre-2012 (p=0.006).
  • Forty percent of women felt that no medications were safe to use in pregnancy, whereas 41 percent selected prednisone (41%), TNFi (15%), NSAIDs (11%), hydroxychloroquine (9%), and acetaminophen (2%) as safe medications.
  • Most women were white (77%), college-educated (68%), and had rheumatoid arthritis (RA) (89%), but other inflammatory arthritis diagnoses were also represented.